What is MRK's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for MRK.

Stock Ratings / Health Care / MRK / options

NVS (67) AZN (67) ABBV (82) JNJ (83) ⌘ Pro Terminal →

Merck & Company Inc. (MRK) Options Positioning, Max Pain & Unusual Sweeps

$148.36 -0.78% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $148.51

Merck & Company Inc. (MRK) earns a Roarable Rating of B+ (Buy) with 80/100 RQD Confidence. High-quality cash engine (74.8% gross margin, 21% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $368.89B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MRK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Merck & Company Inc. (NYSE: MRK) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 80/100 at a spot price of $148.36 (-0.78% 1D, market cap $368.89B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, MRK ranks #15 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MRK compare to NVS and AZN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRK carries a Roarable B+ (80/100 RQD), trailing P/E of 19.8x, gross margin of 74.8%, and ROIC of 20.7%. By comparison, NVS (Novartis AG) holds a C+ grade (67/100 RQD, P/E 32.8x, ROIC 9.9%, cap $306.81B) and AZN (AstraZeneca PLC) posts a C+ grade (67/100 RQD, P/E 32.8x, ROIC 9.9%, cap $289.44B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MRK?

▼

Per MRK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000310158), Merck & Company Inc. generated $65.01B in revenue (+1.3% YoY), $18.25B in net income, and $12.36B in free cash flow against $136.87B in total assets and $46.75B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $148.51 (+0.10%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 19% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 80/100 (B+) historically ranked in the Top 9% of excess returns over the next 90 days (+8.2% avg 90D alpha vs SPY • 71.3% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MRK)Realized 20D OHLCV Swing Band: ±6.7%

Deterministic 5-Pillar Attribution (80/100 Composite)

🔍 WHY MRK SCORES 80/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (24% of score)

20D Institutional Volume Accumulation (±6.7% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (20% of score)

Altman Z-Score 5.19 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Cash Engine Quality14/20 pts (-6 pt drag)

Capital intensity & 33.1% operating margin leave 6 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$147.37+1.7% Next Q

Q2 (-2Q)

Grade B+$149.88-6% Next Q

Q3 (-1Q)

Grade B+$140.93+5.3% Next Q

Current

Grade B+$148.36+8.2% Hist 90D α

Trajectory: B (72) → B+ (80)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MRK Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 80/100 (B+) score, MRK faces multiple-compression risk if 19.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 72.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($146.51) or 200D SMA ($127.27) invalidates the momentum regime and cuts Target Base ($163.05) toward Bear Floor ($121.66).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MRK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MRK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 80%NO 20%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±6.7%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (MRK)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for MRK.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating MRK & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on MRK
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MRK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +31.16%📐 WEDGE COMPRESSION COIL

2026-11-03O $146.3H $149.5L $146.3C $148.4VOL 12.35M

RES: $153.4SUP: $140.5SMA50: $146.5SMA200: $127.3

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MRK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MRK Butterfly Map → + Track MRK →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

13.3%/yr Implied 5Y Growth

vs. +1.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MRK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MRK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MRK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MRK)

Health Care Rank #15 of 1015 ⚔️ NVS vs MRK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MRK vs. NVS, AZN, ABBV, JNJ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Merck & Company Inc. (MRK) ranks #15 by composite RQD confidence (80/100, grade B+) and #4 by equity capitalization ($368.89B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. JNJ currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with MRK at 80/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MRK ACTIVE Merck & Company Inc.	B+	80/100	19.8x	74.8%	20.7%	-0.78%	$368.89B	Benchmark Subject
NVS Novartis AG	C+	67/100	32.8x	—	9.9%	+0.45%	$306.81B	/nvs-vs-mrk →
AZN AstraZeneca PLC	C+	67/100	32.8x	—	9.9%	-0.04%	$289.44B	/azn-vs-mrk →
ABBV AbbVie Inc.	A-	82/100	121.6x	70.2%	29.0%	-2.05%	$521.11B	/abbv-vs-mrk →
JNJ Johnson & Johnson	A-	83/100	24.7x	67.9%	25.5%	-0.97%	$657.68B	/jnj-vs-mrk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000310158 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Merck & Company Inc. (MRK) reported GAAP revenue of $65.01B (+1.3% vs. FY2024 revenue of $64.17B , and +8.1% cumulative change since FY2023) , GAAP net income of $18.25B, operating cash flow of $16.47B, and free cash flow of $12.36B (-31.7% YoY). On the balance sheet, MRK closed FY2025 with $136.87B in total assets against $46.75B in total debt (Altman Z-Score: 5.19, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$65.01B	$18.25B	$16.47B	$12.36B	$136.87B	$46.75B
FY2024 (FY)	2024-12-31	$64.17B	$17.12B	$21.47B	$18.10B	$117.11B	$34.46B
FY2023 (FY)	2023-12-31	$60.12B	$365.0M	$13.01B	$10.30B	$198.56B	$46.46B

3. MRK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MRK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MRK compare to NVS and AZN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MRK?

Where is MRK trading relative to its 50-day, 200-day, and 52-week technical levels?

MRK last traded at $148.36 (-0.78% on volume of 9,095,446 shares), positioning the stock +1.26% above its 50-day simple moving average ($146.51) and +16.57% above its 200-day simple moving average ($127.27). Across its 52-week range of $82.01 to $156.92, MRK sits at the 88.6% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.7% ($138.42 to $158.30).

Direct Sub-Reports: MRK RQD Cockpit MRK 12M Forecast MRK Earnings & Move MRK Dividends & DRIP MRK Insiders & 13F MRK Whale Options MRK Profit Sankey MRK News & Why

ROARABLE RATING BRIEF • RQD 80/100 (B+) ✓ SEC XBRL & RQD VERIFIED

MRK — Merck & Company Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Merck & Company Inc. (MRK) earns a live Roarable RQD composite score of 80/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $148.36 (-0.78% 1D, market capitalization $368.89B).

Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 20.7%, gross margin of 74.8%, operating margin of 34.3%, and free cash flow yield of 3.42%.
Whale 13F & Options Flow (19/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (15/20) + Forensic Balance Sheet (16/20): Incorporates a 0.92x equity beta, Altman Z-Score of 5.19, Piotroski F-Score of 7/9, and Debt/Equity of 0.89x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Merck & Company Inc. Is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The company's gross margin of 74.8% and operating margin of 34.3% (per the market data) indicate a high-margin pharmaceutical profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Merck & Company Inc. (MRK) reported $65.01B in annual revenue (up from $64.17B in FY2024, +1.3% YoY) and $18.25B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($60.12B revenue, $365.0M net income) through FY2025, MRK scaled operating cash flow to $16.47B and free cash flow to $12.36B, backed by $136.87B in total assets against $46.75B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 80/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $82.01 – $156.92 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 19.8x trailing P/E and 15.3x EV/EBITDA against 34.3% operating margins and a 0.92x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context is the Health Care classification and the Biotechnology: Pharmaceutical Preparations industry label. The beta of 0.92 (per the market data) is the sole quantitative indication of market co-movement.

Key Question #1: Can MRK sustain or expand its 34.3% operating margin and 20.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $65.01B and free cash flow of $12.36B, how will capital allocation balance growth reinvestment against $46.75B in total debt?
Key Question #3: How sensitive is MRK's 18.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.92x)?

MRK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Merck & Company Inc. (MRK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MRK Debate Forum (3) ↓

🟢 CATALYST TradingView • 23h ago

Merck & Company, Inc. Stock 12‑Month Price Target Raised to $157.72, Implies 8% Upside

TradingView report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Merck & Company, Inc. (MRK) Stock Forecasts

Yahoo Finance report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Merck & Company (MRK) Receives a Buy from Guggenheim

The Globe and Mail report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Merck Stock Price Forecast. Should You Buy MRK?

StockInvest.us report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Merck appoints Paul Diaz to its board of directors

The Globe and Mail report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Kalkine Media • 1d ago

Is Merck (NYSE:MRK) Stock A Bargain Despite Its Strong Rally?

Kalkine Media report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Merck (MRK) Rallies 5.12% to $148.15 as Buyers Push Toward Upper Range - Synthetic Long

https://www.siam.in/ report covering Merck & Company Inc. (MRK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 1d ago

Eli Lilly Jumped 6% After Earnings. It’s Up 68% in a Year. Where Does the Target Go Now?

Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that won't repeat raise real questions about whether the rally holds from here.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MRK Bull vs. Bear Conversation Board — What's Your Call at $148.36?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MRK 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $189.89 (+27.0%)

📌 Pinned Debate

The forensic balance sheet scores 16/20 with an Altman Z-Score of 5.19 and ROIC of 20.7%, indicating a financially sturdy company with

The forensic balance sheet scores 16/20 with an Altman Z-Score of 5.19 and ROIC of 20.7%, indicating a financially sturdy company with strong capital efficiency.. When you look under the hood at MRK, Fundamental Cash Engine is 14/20 with 74.8% gross margins and 20.7% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (19/20) has been quietly accumulating below $156.92. My 12M target is $189.89.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on 19.8x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (74.8%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $116.63 (-22.0%)

Spot @ $149.52

Free cash flow fell from $18.10B in FY 2024 to $12.36B in FY 2025 while debt rose from $34.46B to $46.75B, and the FCF yield of

Careful chasing MRK at $149.52. Free cash flow fell from $18.10B in FY 2024 to $12.36B in FY 2025 while debt rose from $34.46B to $46.75B, and the FCF yield of 3.42% offers a modest cash return at this valuation.. Gross margin is 74.8%, but operating margin is 34.3%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $116.63 on multiple compression.